Three separate controlled, 2-period, studies in healthy volunteers assessed the pharmacokinetic (PK) interactions between tipranavir/ritonavir (TPV/r) 500/200 mg and 500 mg clarithromycin (CLR), 100 mg fluconazole (FCZ) and 150 mg rifabutin (RFB).
Introduction
The treatment of human immunodeficiency virus (HIV) infected patients with highly active antiretroviral therapy (HAART) has greatly improved life expectancy over the years (14) . Nevertheless, opportunistic infections in people living with HIV continue to be a threat to their health. Drug treatment of these opportunistic infections can be challenging because of the possible drug interactions between HAART and other drugs.
This article presents the results of three interaction studies between tipranavir coadministered with low-dose ritonavir, and clarithromycin, fluconazole and rifabutin in healthy adult volunteers.
Tipranavir (TPV) is an approved protease inhibitor (PI) with potent activity against PIresistant HIV-1. Tipranavir is highly plasma protein bound (99.98%) and is a substrate as well as an inducer of cytochrome P450 (CYP) 3A. (5, 18). To achieve effective plasma TPV concentrations and a twice-daily dosing regimen in treatment experienced patients, co-administration of 500 mg of TPV with 200 mg of ritonavir (TPV/r) is needed.
Clarithromycin (CLR) is a macrolide antibacterial that is used extensively by people living with HIV/AIDS. In addition to its multiple anti-bacterial effects, clarithromycin may be used for both prophylaxis and treatment of Mycobacterium avium complex infections in AIDS. Clarithromycin is a substrate and an inhibitor of cytochrome P450 CYP3A. The primary metabolite is 14-hydroxy-R-clarithromycin (14-OH-CLR) which is the most active of the CLR metabolites (1). The objectives for these three drug interaction studies were to investigate the pharmacokinetic effects of TPV/r on the pharmacokinetics of clarithromycin, fluconazole and rifabutin and vice versa. The secondary objective for each study was to investigate safety and tolerability of the study regimens. 
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Materials and Methods
These studies were conducted in HIV negative healthy male and female subjects. The study designs are summarized in Figure 1 The studies were approved by an Independent Ethics Committee, and all subjects gave written informed consent before any study related procedure could take place. All three studies were conducted at MDS Pharma Services, St. Laurent, Quebec, Canada. The studies were conducted in compliance with the ICH guidelines, the Declaration of Helsinki 1996, and the Canadian Therapeutic Product Directorate guidelines. For each study a detailed set of inclusion and exclusion criteria was defined. In general, male and female subjects (18 to 60 years of age) had to be non-smoking, in good health, have laboratory values less than or equal to Grade 1 based on the ACTG Grading Scale, have an acceptable medical history, physical examination and 12-lead ECG, a healthy chest Xray, if deemed necessary to establish good health of subject by the investigator, able to give informed consent and adhere to the study protocol. Major exclusion criteria included: serological evidence of HBV, HCV and/or HIV infection, a seated systolic blood pressure either <100 mm Hg or >150 mm Hg; resting heart rate either <50 beats/min or >90 beats/min, pregnancy, breastfeeding, non-use of barrier contraception for females, use of hormonal contraception or hormone replacement therapy, recent participation in another drug trial, recent blood or plasma donations, use of any other drugs, and alcohol or substance abuse.
Study design: clarithromycin interaction
The subjects were administered clarithromycin 500 mg BID from study day 1 until the morning of study day 13. Twice daily TPV/r 500 mg/200 mg was initiated on study day 6 and continued until the last dose on the morning of study day 13. Study drugs were taken with 240 mL water on an empty stomach on PK study days and with a light snack on other days. Steady state pharmacokinetic profiles for clarithromycin were obtained on study days 5 and 13 (clarithromycin + TPV/r), and the effect of first dose TPV/r on clarithromycin was evaluated from pharmacokinetic profiles obtained on day 6
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on November 12, 2017 by guest http://aac.asm.org/ Downloaded from (clarithromycin + first dose TPV/r). For the pharmacokinetic profiles, blood samples were obtained just before (nominal time, 0 hours) and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after drug intake in the morning. The effect of clarithromycin on plasma TPV was determined by comparing the TPV pharmacokinetic parameters on study day 13 to TPV data from a pharmacokinetic analysis of 68 healthy volunteers from 4 clinical studies (12, 18, 25, 29) . Ritonavir concentrations were not measured in this study.
Study design: fluconazole interaction
The subjects were administered a loading dose of 200 mg fluconazole on study day 1 followed by a daily 100 mg fluconazole dose for the remainder of the study. On study day 7 the subjects were started on a twice daily dosing regimen with TPV/r 500 mg/200 mg. TPV/r treatment was continued until the last dose on the evening of study day 13. On study days 6, 7 and 13 pharmacokinetic sampling was done just before (nominal time, 0 hours) and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours after drug intake in the morning. Study drugs were taken with 240 mL water on an empty stomach on PK study days and with a light snack on other days. Steady state pharmacokinetic profiles for fluconazole were obtained on study days 6 and 13 (fluconazole + TPV/r), and the effect of first dose TPV/r on fluconazole was evaluated from pharmacokinetic profiles obtained on day 7 (fluconazole + first dose TPV/r). The effect of fluconazole on TPV was determined by comparing the tipranavir pharmacokinetic parameters on study day 13 to TPV data from a pharmacokinetic analysis of 68 healthy volunteers from 4 clinical studies (12, 18, 25, 29) Ritonavir concentrations were not measured in this study.
Study design: rifabutin interaction
The subjects were administered a single dose of rifabutin 150 mg on study day 1.
Pharmacokinetic plasma sampling was done just before dosing (nominal time, 0 hours) and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, 120 , and 144 hours after drug intake. On study day 8 subjects started with TPV/r 500/200 mg twice daily and continued until study day 20. On study day 14 pharmacokinetic sampling was done for tipranavir CLR. Intra-day and inter-day accuracy and precision were ≤7.3%, ≤13.2%, ≤6.4% and ≤6.0%, respectively for clarithromycin. For 14-OH-CLR these results were ≤6.5%, ≤6.3%, ≤8.1% and ≤9.1%. and ammonium hydroxide were added to a 100 µL sample aliquot, then fortified with 20 µL of internal standard working solution. Samples were vortexed, centrifuged, and the organic layer was transferred to tubes containing a 100% butyl ether keeper solution.
Samples were evaporated and the remaining residue was reconstituted with 500 µL of mobile phase and hexane was added. Samples were vortexed, centrifuged, and the hexane layer was aspirated to waste. The remaining solution was injected. The calibration curve ranged from 2.00 to 800 ng/mL for rifabutin and 25-O-desacetyl-rifabutin. Intra-day and inter-day accuracy and precision were ≤8.3%, ≤6.8%, ≤3.2% and ≤2.5%, respectively for rifabutin. For 25-O-desacetyl-rifabutin these results were ≤5.6%, ≤5.0%, ≤5.1% and ≤3.4%.
Tipranavir
Plasma samples were analyzed for tipranavir with a validated liquid chromatography tandem mass spectrometry (LC/MS/MS) method at BASi Analytics, West Lafayette, Indiana, USA. Tipranavir and the internal standard were extracted from human heparinized plasma by a two-step liquid/liquid extraction method that used an ethyl acetate/hexane mixture followed by a hexane wash. The analytes were separated and detected by an LC/MS/MS system that used a 2.0 x 30 mm Synergi Polar RP column with a formic acid/acetic acid/acetonitrile mobile phase. The high calibration curve ranged from 1,000 ng/mL to 20,000 ng/mL. The low calibration curve ranged from 25.0 ng/mL to 2,000 ng/mL. Intra-day and inter-day accuracy and precision were ≤4.9%,
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on November 12, 2017 by guest http://aac.asm.org/ Downloaded from ≤2.4%, ≤6.8% and ≤6.1%, respectively for the high range. For the low range these results were ≤5.2%, ≤1.4%, ≤6.3% and ≤7.8%. In the rifabutin study, because 25-O-desacetyl-RFB has an antimicrobial activity equal to the parent drug, the PK of both compounds will be addressed using the sum of the RFB and 25-O-desacetyl-RFB AUC0-∞, Cmax, and Cp12h, in addition to the analysis of parent and metabolite alone. Results were converted using µM equivalents (RFB, molecular weight 847.02 and 25-O-desacetyl-RFB, molecular weight 804.97).
Pharmacokinetic analysis

Non
Adverse events
Subject safety was monitored by assessment of all adverse events (AEs) at each visit, in addition to laboratory assessment of safety parameters including hematology, chemistry, liver function tests (AST, ALT, alkaline phosphatase, total bilirubin), and lipid parameters (triglycerides, cholesterol) at screening and on various days throughout the studies. 
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Statistical analysis was done with SAS (Release 8.2; SAS Institute Inc., Cary, NC). For clarithromycin, fluconazole, rifabutin and tipranavir, the pharmacokinetic parameters AUC, Cmax and Cp12h or Cp24 geometric means were calculated. The ratio of the geometric means of the test regimen to the reference regimen was used to asses the interaction (30). The null hypothesis was that the ratio being tested lies either below the lower boundary of relevance (0.80) or above the upper boundary of relevance (1.25). The alternative hypothesis was that the ratio lies within the relevance boundaries. The null hypothesis was tested using the methodology of two one-sided tests, i.e., the null hypothesis was rejected in favor of absence of a relevant interaction if the 90% confidence interval on the ratio was completely contained in the acceptance region of 0.80 -1. 25 . The 90% confidence interval on the ratio was derived by exponentiation of the confidence interval from the logarithmic scale.
For tipranavir co-administered with clarithromycin or fluconazole, SAS Proc Multtest was used to resample tipranavir AUC 0-12h , Cmax and Cp 12h pharmacokinetic results from 4 healthy volunteer clinical studies (12, 18, 25, 29) and from the respective drug interaction studies. Bootstrap arithmetic means (2000 resamples) were determined and the ratio of the means of the test regimen to the reference regimen was used to asses the interaction and determine the point estimate. The 5 th and 95 th percentiles of the distribution of the ratios provided the 90% confidence interval.
The sample size for the clarithromycin and rifabutin studies was based on tipranavir data that were on file. This was done because clarithromycin within subject variation in AUC was similar to that for tipranavir whereas for rifabutin no within subject variation data was available, however between subject variation was similar to that of tipranavir. Based on this data, 18 subjects were required to ensure the studies would have a 90% power to reject both the null hypothesis that the ratio of the test mean to the standard mean is below 80% and the null hypothesis that the ratio of test mean to the standard mean is above 125%; i.e., that the test and standard are not equivalent, in favor of the alternative hypothesis that the means of the two groups are equivalent, assuming that the expected
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For the fluconazole study data from a previous study done by Boehringer Ingelheim was used to calculate the fluconazole intra-individual coefficient of variation. Fluconazole
Cmax had a higher coefficient of variation and was used for the sample size calculation.
For an expected reduction of PK parameters for fluconazole of 5%, a sample size of 14 subjects was expected to result in a probability of 92% (power) that a 90% CI was included in the acceptance range of 80% -125%. To allow for drop outs it was decided to include 20 subjects in the study.
Results
Clarithromycin Study
Twenty-four healthy volunteers (7 females and 17 males) were enrolled and completed the study. Two subjects were black and 22 were white. The mean ± SD age, weight and height for the study population was 33.2 ± 9.2 years, 75.3 ± 12.3 kg and 173.5 ± 10.5 cm, respectively.
Pharmacokinetic results for study days 10 and 13 were based on 21 subjects due to recurrent vomiting by 3 subjects. Table 1 summarizes the geometric mean ratios and 90%
confidence intervals for AUC0-12h, Cmax and Cp12h for CLR, 14-OH-CLR in the presence and absence of single dose (sd) and multiple dose tipranavir (comparisons made between the different study days). Table 2 summarizes the observed values for the main pharmacokinetic parameters for the studied compounds on the different study days. decreased by 61% and 95% after single and multiple doses of TPV/r, respectively.
Multiple dose of TPV/r also resulted in a 97% decrease in both AUC0-12 and Cmax of 14-OH-CLR. When steady-state clarithromycin 500 mg twice-daily was co-administered with TPV/r 500/200 mg twice-daily, the TPV AUC0-12h, Cmax, and Cp12h increased 66%, 40% and 100%, respectively, when compared to the healthy volunteer historical control population (Table 1) .
No serious adverse events occurred during this study. There were no discontinuations due ALT level during the clarithromycin + TPV/r phase and one subject having a grade 3 lipase elevation during the clarithromycin-only phase, there were no clinically relevant laboratory abnormalities.
Fluconazole Study
Twenty healthy volunteers (2 females and 18 males) were enrolled and completed the study. One subject was black, 19 were white. The mean ± SD age, weight and height for the study population was 42.4 ± 11.0 years, 75.9 ± 9.5 kg and 175.7 ± 6.8 cm, respectively.
Pharmacokinetic results for fluconazole are available for 19 subjects; the results for one subject were omitted because of an anomalous Cp24 for fluconazole on study day 6. Table 3 summarizes the geometric mean ratios and 90% confidence intervals for AUC0-24h, Cmax and Cp24 for fluconazole in the comparisons made between the different study days. Table 4 summarizes the observed values for the main pharmacokinetic parameters for fluconazole and tipranavir on the different study days. Figure 6 illustrates the individual values for the 19 subjects for AUC, Cmax and Cp12 for FCZ, before and after the addition of TPV/r to the regimen.
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The effect of single dose TPV/r 500/200 mg on fluconazole AUC, Cmax and Cp12h was minimal (<3%) ( Table 3) . After multiple dose TPV/r the decrease in fluconazole exposure was <12%. In both dosing situations the 90% confidence intervals of the GMR were within the bioequivalence limits of 0.80 -1.25.
When steady-state fluconazole 100 mg once-daily was co-administered with TPV/r 500/200 mg twice-daily, the TPV AUC0-12h, Cmax, and Cp12h increased 50%, 32% and 69%, respectively, when compared to the healthy volunteer historical control population (Table 3) .
No serious adverse events occurred during this study. There were no discontinuations due to Aes or any other reason. The most frequently observed adverse events were gastrointestinal-related (35% loose stool, 20% nausea and 15% lower abdominal pain).
Dizziness (excluding vertigo that was not observed in this study) and somnolence accounted for 20% each. The majority of these events were of mild to moderate intensity with 16 subjects (80%) having mild events and 2 subjects (10%) having moderate events.
There were no clinically relevant variations from baseline in the results of laboratory tests during the co-administration of TPV/r plus fluconazole. Relative to fluconazole alone, TPV/r plus fluconazole treatment resulted in a median 2.1-fold increase in ALT and 1.5
fold increase in AST, however no clinical adverse symptoms or events were associated.
There were no relevant differences in the medians of other liver function test parameters between fluconazole alone and TPV/r plus fluconazole treatments.
Rifabutin study
Twenty-four healthy volunteers (4 females and 20 males) were enrolled and 20 completed the study; four subjects were discontinued due to adverse events. Twenty-two subjects were white and two were black. The mean ± SD age, weight and height for the study population was 32.8 ± 8.5 years, 73.2 ± 8.9 kg and 173.8 ± 8.6 cm, respectively.
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Three subjects withdrew from the study prior to study day 15 and 1 subject withdrew from the study on study day 16. Therefore, pharmacokinetic results were available for 20 subjects for RFB and 25-O-desacetyl-RFB, while results for 21 subjects were available for TPV pharmacokinetics. Table 5 Co-administration of single-dose RFB with steady-state TPV/r did not affect the primary TPV pharmacokinetic parameters AUC0-12h or Cmax, and caused only a small, but statistically significant 16% increase in Cp12h.
Eighteen subjects (75%) reported at least one AE while receiving TPV/r. The most frequently reported Aes were related to the gastrointestinal tract (reported by 14 subjects (58.4%); nausea (33.3%) and vomiting (25%)), and the central nervous system (reported by 11 subjects (45.8%); headaches (33.3%) and dizziness (12.5%)). All Aes during treatment with TPV/r were of mild to moderate DAIDS grade severity with 18 subjects (75%) reporting mild events, and 3 subjects (12.5%) reporting moderate events. Five subjects were found to have clinically relevant laboratory test abnormalities. Three subjects developed asymptomatic ≥ DAIDS grade 3 levels of ALT or AST, which led to their early discontinuation from the study. In all 3 subjects, ALT and AST levels returned to normal by a follow-up visit approximately 1 month following the end of the study. A grade 3 elevation in lipase level (on day 21) and a grade 4 elevation in PPT level (on day 8) were also reported during the study; these levels returned to normal 1 week later.
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A fourth subject was discontinued due to the appearance of generalized rash, which resolved after 5 days. All the Aes that led to discontinuations occurred during the TPV/r treatment period.
DISCUSSION
This article presents three healthy volunteer studies which investigated the pharmacokinetic interaction between tipranavir co-administered with low-dose ritonavir and each of the antimicrobial drugs clarithromycin, fluconazole and rifabutin. These drug combinations are frequently needed in the treatment of HIV infected patients, and therefore pharmacokinetic drug-drug interaction studies of these combinations were warranted.
Clarithromycin study pharmacokinetics
In the clarithromycin study, it was found that clarithromycin AUC and Cp12h increased 19% and 68%, while Cmax decreased 5%, after co-administration with TPV/r at steady state. The effect of TPV/r on 14-hydroxy-clarithromycin was greater and almost completely (>95%) inhibited the formation of this metabolite. These observations are consistent with previously published results with other protease inhibitors. In an interaction study with ritonavir 200 mg tid and clarithromycin 500 mg bid, increases were seen in clarithromycin AUC, Cmax and Cmin of 77%, 31% and 182%, respectively. Also in this study, the formation of 14-hydroxy-clarithromycin was inhibited strongly (>99%) (20) . In an interaction study with indinavir 800 mg tid and clarithromycin 500 mg bid, it was found that clarithromycin AUC and Cmax increased 47% and 19%, respectively, while 14-hydroxy-clarithromycin AUC and Cmax decreased by 49% and 48% (7). When combining amprenavir 1200 mg bid with clarithromycin 500 mg bid, there was only a small effect (<10%) on clarithromycin AUC, Cmax and Cp12h, however for 14-hydroxyclarithromycin these parameters were decreased by 35%, 32% and 4%, respectively (8) .
In this last study it was noticed that the renal clearance of clarithromycin increased 34%
when combined with amprenavir. This observation can explain the relatively low increase in clarithromycin AUC in this combination. Similarly, in the present study the relatively The increase in tipranavir exposure of 66%, in comparison to the healthy volunteer historical controls, can be explained by the inhibitory effects of clarithromycin on CYP3A isozymes. For amprenavir, indinavir and ritonavir, increases in the AUC of 18%, 19% and 12%, respectively, have been reported when combined with clarithromycin (7, 8, 20) .
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Fluconazole study pharmacokinetics
In the FCZ study, co-administration of two doses of TPV/r 500/200 mg did not substantially influence the steady-state pharmacokinetics of FCZ (changes in the AUC0-24h, Cmax, and Cp24h ≤ 3%). Co-administration of TPV/r 500/200 mg twice-daily for 7 days caused small, but statistically significant decreases in the FCZ AUC0-24h (-8%), Cmax (-6%), and Cp24h (-11%). However, these minor changes are not considered to be clinically significant. The absence of a clinically relevant effect of TPV/r on FCZ pharmacokinetics can be explained by the fact that FCZ is cleared primarily by renal excretion with approximately 80% of the administered dose appearing in the urine as unchanged drug. About 11% of the dose is excreted in the urine as metabolites. FCZ has only a weak affinity of human cytochrome P450 metabolic enzymes. However, the increases in steady-state AUC0-12h, Cmax and Cp12h of TPV, compared to the healthy volunteer historical controls, might be explained by the inhibitory effect of FCZ on CYP3A mediated metabolism (10, 17) , the main enzyme for the metabolism of both TPV and RTV. increased by 50% and 56%, respectively, during co-administration of FCZ (200 mg oncedaily) in a small study in five HIV-1 infected patients (17) . In the same study, no effect of FCZ on the pharmacokinetics of RTV (600 mg twice-daily) was observed (n=3). In a study in 11 HIV-1-infected patients, co-administration of FCZ (400 mg once-daily) and indinavir (1,000 mg thrice-daily) caused a marginally statistically significant decrease in the AUC0-8h of indinavir (-24%), with no substantial effect on Cmax or Cp8h (13) . The reduction of the indinavir AUC might be explained by potential interference of FCZ with indinavir absorption, or induction of certain CYP450 enzymes by FCZ.
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An increase in the Cmax (+82%) and a decrease in the CL/F (-36%) of TPV was observed during co-administration of TPV/r and FCZ compared to the results population PK analysis, suggesting that FCZ inhibited both intestinal and hepatic CYP3A enzymes. This is in agreement with the results of a previously published pharmacokinetic interaction study of oral FCZ with intravenous and oral midazolam, which is a well known substrate for CYP3A (19) .
Rifabutin study pharmacokinetics
In the rifabutin study, the effect of a single 150mg dose of RFB on the steady-state pharmacokinetics of TPV (co-administered with RTV) was limited to a 16% increase in Cp12h with no apparent effect on AUC0-12h or Cmax. This is in line with the knowledge that RFB-mediated CYP3A induction requires approximately one week of daily drug administration (9, 22) . Therefore, an RFB-dependent CYP3A induction effect was unlikely to occur since this study was limited to investigating the interactions between single-dose of RFB and steady-state TPV/r. However from several reports it seems that multiple dose rifabutin in healthy volunteers might lead to unacceptable adverse events (6, 15, 28) . literature (21, 26, 27) . Finally, patients receiving RFB with TPV/r should be closely monitored for emergence of adverse events associated with RFB therapy.
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In terms of safety, these studies were conducted in healthy male and female subjects between 18 and 60 years of age. Consistent with previous TPV trials, the most frequently observed Aes were GI related. In general, the treatments in the clarithromycin and fluconazole studies were well-tolerated with the majority of AE's being mild in intensity.
The clinically non relevant increases in ALT and AST in the fluconazole study seem to be concordant with a report of liver toxicity being related to fluconazole use in tuberculosis treatment (23) .
In the rifabutin study five subjects were found to have clinically relevant changes in laboratory measurements in this study. Three subjects developed asymptomatic Grades 3 and 4 levels of ALT and AST which led to their early discontinuation from the study. A fourth subject was discontinued due to the appearance of generalized rash. All the Aes that led to discontinuations occurred during the TPV/r treatment period. Overall, the RFB and TPV/r combination treatment was moderately tolerated.
Conclusion
In conclusion, when combining tipranavir with clarithromycin it should be noted that both tipranavir and clarithromycin exposure will be increased. For clarithromycin this will not cause problems in patients with a normal renal function. However, while concentration-related adverse events have not been observed in studies with TPV (2, 24), patients using clarithromycin at doses higher than 500 mg BID should be carefully monitored for signs of toxicity. The almost complete inhibition of formation of 14-OH-CLR should be taken in account when treating pathogens susceptible to this pharmacologically active metabolite. Overall, the TPV/r/CLR combination treatment was moderately-tolerated in the healthy subject population used in this study, however it is not clear if this is a result of the increase in CLR exposure. 
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